Cargando…
Amplified therapeutic targets in high-grade serous ovarian carcinoma – a review of the literature with quantitative appraisal
High-grade serous ovarian carcinoma is a unique cancer characterised by universal TP53 mutations and widespread copy number alterations. These copy number alterations include deletion of tumour suppressors and amplification of driver oncogenes. Given their key oncogenic roles, amplified driver genes...
Autores principales: | Talbot, Thomas, Lu, Haonan, Aboagye, Eric O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940086/ https://www.ncbi.nlm.nih.gov/pubmed/36804485 http://dx.doi.org/10.1038/s41417-023-00589-z |
Ejemplares similares
-
Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer
por: Lu, Haonan, et al.
Publicado: (2021) -
Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018) -
The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma
por: Chesnokov, Mikhail S., et al.
Publicado: (2021) -
Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer
por: Lu, Haonan, et al.
Publicado: (2023) -
Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets
por: Voutsadakis, Ioannis A
Publicado: (2020)